These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 6486990)
21. In vitro susceptibility of mycobacterium fortuitum and mycobacterium chelonei to cefoxitin. Casal M; Rodríguez F Tubercle; 1982 Jun; 63(2):125-7. PubMed ID: 7179478 [No Abstract] [Full Text] [Related]
22. Therapy of infections caused by 'atypical' mycobacteria. Grange JM J Antimicrob Chemother; 1984 Apr; 13(4):308-10. PubMed ID: 6725182 [No Abstract] [Full Text] [Related]
23. Drug susceptibility testing of nontuberculous mycobacteria. van Ingen J; Kuijper EJ Future Microbiol; 2014; 9(9):1095-110. PubMed ID: 25340838 [TBL] [Abstract][Full Text] [Related]
24. Antimicrobial activity of ofloxacin and other agents against mycobacterial isolates from postoperative sternotomy wounds. Yew WW; Kwan SY; Ma WK; Lui KS; Aung MK Clin Ther; 1989; 11(6):775-85. PubMed ID: 2611821 [TBL] [Abstract][Full Text] [Related]
27. Nontuberculous mycobacterial ocular infections--comparing the clinical and microbiological characteristics between Mycobacterium abscessus and Mycobacterium massiliense. Chu HS; Chang SC; Shen EP; Hu FR PLoS One; 2015; 10(1):e0116236. PubMed ID: 25581038 [TBL] [Abstract][Full Text] [Related]
28. Successful treatment of pulmonary infection due to Mycobacterium chelonae: case report and review. Singh N; Yu VL Clin Infect Dis; 1992 Jan; 14(1):156-61. PubMed ID: 1571422 [TBL] [Abstract][Full Text] [Related]
29. Sulfonamide activity against Mycobacterium fortuitum and Mycobacterium chelonei. Wallace RJ; Jones DB; Wiss K Rev Infect Dis; 1981; 3(5):898-904. PubMed ID: 7339821 [TBL] [Abstract][Full Text] [Related]
30. Activities of cefoxitin and cefotetan against Mycobacterium fortuitum infections in mice. Saito H; Sato K; Jin BW Antimicrob Agents Chemother; 1984 Aug; 26(2):270-1. PubMed ID: 6592999 [TBL] [Abstract][Full Text] [Related]
31. [A case of bronchial ulcer due to infection by Mycobacterium abscessus]. Kasai S; Tokuda H; Yoshikawa M; Nishiyama H Nihon Kokyuki Gakkai Zasshi; 2004 Oct; 42(10):919-23. PubMed ID: 15566008 [TBL] [Abstract][Full Text] [Related]
32. Promising new drugs in the treatment of tuberculosis and mycobacteriosis. Casal M; Rodríguez F; Gutierrez J; Ruiz P; Benavente MC; Villalba R; Moreno G J Chemother; 1989 Feb; 1(1):39-45. PubMed ID: 2498468 [TBL] [Abstract][Full Text] [Related]
38. A single 16S ribosomal RNA substitution is responsible for resistance to amikacin and other 2-deoxystreptamine aminoglycosides in Mycobacterium abscessus and Mycobacterium chelonae. Prammananan T; Sander P; Brown BA; Frischkorn K; Onyi GO; Zhang Y; Böttger EC; Wallace RJ J Infect Dis; 1998 Jun; 177(6):1573-81. PubMed ID: 9607835 [TBL] [Abstract][Full Text] [Related]
39. Combination of ofloxacin and amikacin in the treatment of sternotomy wound infection. Yew WW; Kwan SY; Ma WK; Aung-khin M; Mok CK Chest; 1989 May; 95(5):1051-5. PubMed ID: 2707062 [TBL] [Abstract][Full Text] [Related]
40. Empiric antibiotic therapy with an amikacin-carbenicillin-cefoxitin combination in granulocytopenic febrile patients--a clinical report. Fernández-Rañada J; Fernández-Garese D; Caretti D; Vázquez L; Escudero A; Olmeda F Int J Clin Pharmacol Ther Toxicol; 1983 Oct; 21(10):511-3. PubMed ID: 6642788 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]